Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT03619213 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03619213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03619213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2018
Completion date
March 27, 2022
Enrollment
6,263 (actual)
Sites
348

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction